Bosh sahifaATYR • NASDAQ
add
aTyr Pharma Inc
5,31 $
Dastlabki sotuv:(1,11%)+0,059
5,37 $
Yopilgan:27-iyn, 8:02:12 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
5,11 $
Kunlik diapazon
5,16 $ - 5,50 $
Yillik diapazon
1,47 $ - 5,98 $
Bozor kapitalizatsiyasi
472,61 mln USD
Oʻrtacha hajm
2,36 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 3,96 mln | 12,89% |
Sof foyda | -14,88 mln | 3,94% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,17 | 26,09% |
EBITDA | -15,61 mln | 5,18% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 76,35 mln | -9,64% |
Jami aktivlari | 97,24 mln | -14,13% |
Jami passivlari | 22,38 mln | -22,73% |
Umumiy kapital | 74,86 mln | — |
Tarqatilgan aksiyalar | 89,00 mln | — |
Narxi/balansdagi bahosi | 6,08 | — |
Aktivlardan daromad | -40,64% | — |
Kapitaldan daromad | -46,13% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -14,88 mln | 3,94% |
Operatsiyalardan naqd pul | -15,42 mln | 31,10% |
Sarmoyadan naqd pul | -4,42 mln | -225,96% |
Moliyadan naqd pul | 18,63 mln | 140,98% |
Naqd pulning sof oʻzgarishi | -1,21 mln | 92,43% |
Boʻsh pul | -9,71 mln | 41,99% |
Haqida
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Tashkil etilgan
1-yan, 2005
Sayt
Xodimlar soni
61
